Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621718 | 0.74 | EGFR (0.54) | EGFRMKNK2PIK3CDPIK3R2 | |
| SCHEMBL29439793 | 0.74 | EGFR (0.54) | EGFRMKNK2PIK3CDPIK3R2 | |
| SCHEMBL2643013 | 0.73 | GCK (0.35) | GCK | |
| SCHEMBL2894172 | 0.73 | GCK (0.52) | EGFRGCK | |
| SCHEMBL16767066 | 0.72 | EGFR (0.59) | EGFRMKNK2 | |
| SCHEMBL28412816 | 0.72 | EGFR (0.71) | EGFRMKNK2 | |
| SCHEMBL2642168 | 0.71 | NPC1 (0.53) | EGFRMKNK2 | |
| SCHEMBL12275900 | 0.71 | EGFR (0.54) | EGFRMKNK2 | |
| SCHEMBL12275851 | 0.70 | EGFR (0.48) | EGFRMKNK2 | |
| SCHEMBL22715501 | 0.70 | MAP4K4 (0.54) | EGFRMKNK2PIK3CDPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | EGFR 3484/4885MKNK2 332/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.